Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Collier

Showing results (41-50 of 184) with videos related to

Pageof 19
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.
Oncology|May 25, 2011
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysisSupriya Krishnan, Jeffrey T Schouten, Denise L Jacobson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2007
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)Pablo Tebas, Jiameng Zhang, Kevin Yarasheski, et al.
AIDS and Behavior|October 28, 2019
A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.SJane M Simoni, Kenneth Tapia, Sung-Jae Lee, et al.
The Journal of Infectious Diseases|November 14, 2009
Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responsesYi Liu, John McNevin, Morgane Rolland, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 13, 2018
Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulationJohn C Kraft, Lisa A McConnachie, Josefin Koehn, et al.
The Journal of Infectious Diseases|May 12, 2007
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virusTae-Wook Chun, J Shawn Justement, Susan Moir, et al.
AIDS (London, England)|December 12, 2013
The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapyJudith J Lok, Peter W Hunt, Ann C Collier, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Lower genitourinary tract sources of seminal HIVRobert W Coombs, David Lockhart, Susan O Ross, et al.
The Journal of Infectious Diseases|November 14, 2012
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202Heather J Ribaudo, Eric S Daar, Camlin Tierney, et al.
Pageof 19

Showing results (41-50 of 184) with videos related to

Sort By:
Pageof 19
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.
Oncology|May 25, 2011
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysisSupriya Krishnan, Jeffrey T Schouten, Denise L Jacobson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2007
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)Pablo Tebas, Jiameng Zhang, Kevin Yarasheski, et al.
AIDS and Behavior|October 28, 2019
A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.SJane M Simoni, Kenneth Tapia, Sung-Jae Lee, et al.
The Journal of Infectious Diseases|November 14, 2009
Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responsesYi Liu, John McNevin, Morgane Rolland, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 13, 2018
Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulationJohn C Kraft, Lisa A McConnachie, Josefin Koehn, et al.
The Journal of Infectious Diseases|May 12, 2007
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virusTae-Wook Chun, J Shawn Justement, Susan Moir, et al.
AIDS (London, England)|December 12, 2013
The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapyJudith J Lok, Peter W Hunt, Ann C Collier, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Lower genitourinary tract sources of seminal HIVRobert W Coombs, David Lockhart, Susan O Ross, et al.
The Journal of Infectious Diseases|November 14, 2012
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202Heather J Ribaudo, Eric S Daar, Camlin Tierney, et al.
Pageof 19